Informace o publikaci

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Autoři	CHNG W.J. GOLDSCHMIDT H. DIMOPOULOS M.A. MOREAU P. JOSHUA D. PALUMBO A. FACON T. LUDWIG H. POUR Luděk NIESVIZKY R. ORIOL A. ROSINOL L. SUVOROV A. GAIDANO G. PIKA T. WEISEL K. GORANOVA-MARINOVA V. GILLENWATER H.H. MOHAMED N. FENG S. AGGARWAL S. HÁJEK R.
Rok publikování	2017
Druh	Článek v odborném periodiku
Časopis / Zdroj	Leukemia
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	http://dx.doi.org/10.1038/leu.2016.390
Doi	http://dx.doi.org/10.1038/leu.2016.390
Obor	Onkologie a hematologie
Klíčová slova	LOW-DOSE DEXAMETHASONE; STEM-CELL TRANSPLANTATION; PLUS DEXAMETHASONE; INTERGROUPE FRANCOPHONE; DELETION 17P; LENALIDOMIDE; THERAPY; ABNORMALITIES; POMALIDOMIDE; THALIDOMIDE
Popis	The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (MM). We conducted a preplanned subgroup analysis of ENDEAVOR to evaluate Kd vs Vd by cytogenetic risk. Of 785 patients with known cytogenetics, 210 (27%) had high-risk cytogenetics (Kd, n=97 [25%]; Vd, n=113 [28%]) and 575 (73%) had standard-risk cytogenetics (Kd, n=284 [75%]; Vd, n=291 [72%]). Median PFS in the high-risk group was 8.8 months for Kd vs 6.0 months for Vd (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.45–0.92; P=0.0075). Median PFS in the standard-risk group was not estimable for Kd vs 10.2 months for Vd (HR, 0.44; 95% CI, 0.33–0.58; P<0.0001). Overall response rates were 72.2% (Kd) vs 58.4% (Vd) in the high-risk group and 79.2% (Kd) vs 66.0% (Vd) in the standard-risk group. In the high-risk group, 15.5% (Kd) vs 4.4% (Vd) achieved a complete response (CR) or better. In the standard-risk group, 13.0% (Kd) vs 7.9% (Vd) achieved greater than or equal toCR. This preplanned subgroup analysis found that Kd was superior to Vd in relapsed or refractory MM, regardless of cytogenetic risk.